Abstract
In Japan, three oral preparations (calcitriol, alfacalcidol and falecalcitriol) and two intravenous preparations (calcitriol and maxacalcitol) are now available for the vitamin D(3) therapy in renal osteodystrophy. In general, oral therapy is indicated for mild cases of secondary hyperparathyroidism (intact PTH<300 pg/mL) to maintain adequate level of serum PTH except "calcitriol oral pulse therapy" for moderate to severe cases. Recently, intravenous therapy has been introduced to treat more severe cases by using the advantage of rapid clearance of these metabolites. In order to use these preparations safely, adequate level of both serum intact PTH (150-300 pg/mL) and Ca/P product (<55) should be maintained to prevent from adynamic bone and vascular calcification.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.